Comparative Pharmacology
Head-to-head clinical analysis: COR OTICIN versus CORTAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COR OTICIN versus CORTAN.
COR-OTICIN vs CORTAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
COR-OTICIN is a combination product containing hydrocortisone (a corticosteroid with anti-inflammatory and immunosuppressive properties) and neomycin (an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit) and polymyxin B (a polymyxin antibiotic that disrupts bacterial cell membrane permeability).
Corticosteroid that binds to the glucocorticoid receptor, leading to anti-inflammatory and immunosuppressive effects by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing cytokine production.
1-2 drops in each affected ear twice daily for 7 days.
5-60 mg orally once daily, titrated to the lowest effective dose. Maintenance: 5-20 mg daily.
None Documented
None Documented
Terminal half-life 4-6 hours; prolonged in renal impairment (up to 12-15 hours)
Terminal elimination half-life 1.5–2 hours; clinical context: short duration requires multiple daily doses for sustained effect
Renal (60-80% unchanged), fecal/biliary (5-10%)
Renal: 80% as metabolites and unchanged drug; biliary/fecal: 20%
Category C
Category C
Topical Corticosteroid + Antibiotic
Topical Corticosteroid